Entandrophragma delevoyi

Entandrophragma delevoyi is presumed, by genus-level chemotaxonomy, to contain limonoid triterpenoids (meliacins) and protolimonoids that suppress pro-inflammatory nitric oxide production and exert antiplasmodial activity, consistent with documented mechanisms in closely related species. Formal species-specific clinical or pharmacological data are absent; all quantified outcomes—such as EC₅₀ values of 81 µM for moluccensin O in LPS-stimulated macrophages—derive from congeners rather than E. delevoyi itself.

Origin & History

Entandrophragma delevoyi is a large timber and medicinal tree in the Meliaceae (mahogany) family, endemic to the rainforest and transitional woodland zones of central and southern Africa, particularly the Democratic Republic of Congo and neighboring regions. Like other members of the genus, it grows in humid tropical conditions, often in lowland and montane forests with deep, well-drained lateritic soils. It has not been subjected to deliberate horticultural cultivation for medicinal purposes and is primarily harvested from wild stands.

Historical & Cultural Context

Entandrophragma delevoyi has been identified in at least one ethnobotanical survey as a medicinal plant used by local communities in central Africa for pain and infectious conditions, representing the inaugural formal documentation of its medicinal status in the scientific literature. The broader Entandrophragma genus has a multi-century history of use in sub-Saharan African traditional medicine, with species such as E. angolense (Gedu nohor) and E. utile (Sipo) used by healers across the Congo Basin, West Africa, and East Africa for fevers, malaria, dysentery, and dermatological infections. Bark preparations—typically decoctions or bark-soaked water drinks—constitute the predominant traditional form across genus members, and this likely applies to E. delevoyi by cultural extension. The genus name Entandrophragma derives from Greek roots referencing the fibrous, interlocked grain of the timber, reflecting the tree's primary historical economic value as a commercial hardwood alongside its medicinal role.

Health Benefits

- **Anti-inflammatory Potential**: Genus-wide limonoids suppress LPS-induced nitric oxide production in RAW 264.7 macrophage models, suggesting E. delevoyi bark extracts may reduce acute inflammatory signaling, though species-specific data are lacking.
- **Antimalarial Activity**: Entandrophragma limonoids from related species demonstrate antiplasmodial activity in vitro, pointing to potential use against Plasmodium falciparum consistent with traditional African anti-fever applications attributed to the genus.
- **Analgesic Use in Traditional Medicine**: Ethnobotanical surveys identify E. delevoyi as a medicinal plant used for pain management, aligning with the genus-wide anti-inflammatory phytochemical profile and community healing practices in central Africa.
- **Antimicrobial Properties**: Meliaceous limonoids broadly exhibit activity against gram-positive bacteria and fungal pathogens in in vitro assays; E. delevoyi is used ethnobotanically for infections, suggesting parallel bioactive potential pending direct testing.
- **Antioxidant Capacity**: The presence of catechin-type polyphenols and triterpenoids documented in closely related Entandrophragma species implies free-radical scavenging capacity, which would support both anti-inflammatory and cytoprotective traditional applications.
- **Wound-Healing Support**: Bark preparations from Meliaceae members are widely used topically in African ethnomedicine for wound care; the astringent tannins and anti-infective limonoids in the genus provide a plausible mechanistic basis for this application in E. delevoyi.

How It Works

Based on genus-level evidence, the primary bioactive scaffold attributed to Entandrophragma species is the limonoid class (meliacins), which inhibit NF-κB-mediated transcription of inducible nitric oxide synthase (iNOS), thereby reducing NO production in activated macrophages—an effect demonstrated for moluccensin O at EC₅₀ ≈ 81 µM and for (−)-catechin glucoside at EC₅₀ ≈ 137 µM in E. angolense isolates. Antiplasmodial limonoids are hypothesized to disrupt mitochondrial electron transport in Plasmodium parasites, consistent with the known mechanism of other malarial Meliaceae compounds such as azadirachtin. Protolimonoids and seco-tirucallane triterpenoids may additionally modulate cyclooxygenase (COX) activity and cytokine release (IL-1β, TNF-α), providing complementary analgesic pathways relevant to E. delevoyi's reported pain-relieving ethnobotanical use. No receptor-binding, transcriptomic, or in vivo mechanistic data specific to E. delevoyi extracts have been published.

Scientific Research

Evidence for E. delevoyi specifically is limited to a single ethnobotanical survey that records it as a medicinal plant—representing the first such documented report—with no phytochemical, pharmacological, or clinical studies conducted on this species to date. The broader Entandrophragma genus has generated approximately 166 catalogued secondary metabolites across species, studied predominantly through in vitro bioassays and limited rodent models, without any registered clinical trials for any member species. Study quality for congeners is generally low (in vitro EC₅₀ determinations, uncontrolled ethnobotanical surveys), precluding extrapolation of effect sizes, therapeutic indices, or safety margins to E. delevoyi. The current evidence base is insufficient to support efficacy claims and underscores the need for systematic phytochemical screening and controlled pharmacological evaluation of E. delevoyi.

Clinical Summary

No clinical trials—randomized, observational, or otherwise—have been conducted on Entandrophragma delevoyi or on any Entandrophragma species. Pharmacological data are restricted to in vitro cellular models (LPS-stimulated RAW 264.7 macrophages, Plasmodium falciparum culture assays) using isolated compounds from related species such as E. angolense and E. cylindricum. Quantified outcomes from these preclinical experiments—such as antiplasmodial IC₅₀ values and anti-inflammatory EC₅₀ ranges—cannot be translated into human effective doses, safety thresholds, or clinical effect sizes. Confidence in any therapeutic claim for E. delevoyi remains very low, and the ingredient should be regarded as a traditional use candidate requiring phytochemical characterization and Phase I safety evaluation before clinical investigation.

Nutritional Profile

No nutritional composition data (macronutrients, micronutrients, or caloric value) have been reported for any edible portion of Entandrophragma delevoyi, as it is not used as a food source. Phytochemical profiling of congeners indicates the likely presence of limonoid triterpenoids (constituting ~69% of genus secondary metabolites), protolimonoids, seco-tirucallane triterpenoids, catechin-type flavan-3-ols (e.g., (−)-catechin glucoside), and phenolic acids in bark tissues, though no quantitative concentrations have been determined for E. delevoyi. Bioavailability of limonoids in humans is poorly characterized even for well-studied Meliaceae compounds such as azadirachtin; oral bioavailability is presumed low due to high molecular weight and limited aqueous solubility, suggesting potential need for lipid-based delivery if ever developed.

Preparation & Dosage

- **Traditional Decoction (Bark)**: Stem or root bark is boiled in water in central African folk practice; volume and concentration are unstandardized and vary by practitioner and indication.
- **Aqueous Extract**: Crude aqueous extracts are the most common preparation method across the Entandrophragma genus in ethnobotanical contexts; no standardized extract ratio or marker-compound percentage has been established for E. delevoyi.
- **Ethanol/Methanol Extract (Research Grade)**: Laboratory studies of congeners use 70–95% ethanol or methanol maceration to isolate limonoids; not available commercially.
- **Effective Dose Range**: No human dose-ranging studies exist; no safe or effective oral dose can be stated for E. delevoyi.
- **Timing and Frequency**: Undocumented; traditional use frequency is not reported in available ethnobotanical literature.
- **Standardization**: No standardization to marker compounds (e.g., specific limonoid content) has been attempted or published for this species.

Synergy & Pairings

No empirically validated synergistic combinations have been documented for E. delevoyi. By analogy with genus-level research, limonoid-containing extracts from Meliaceae species have shown additive antiplasmodial effects when combined with artemisinin-class compounds in in vitro models, suggesting a potential complementary mechanism targeting parasite mitochondria and heme detoxification pathways simultaneously. Traditional healers in central Africa commonly combine Entandrophragma bark preparations with other anti-infective plants such as Nauclea latifolia or Vernonia amygdalina, though no pharmacological investigation of these combinations involving E. delevoyi has been reported.

Safety & Interactions

No human safety data, toxicology studies, or adverse event reports exist for Entandrophragma delevoyi, making it impossible to establish a safe dose, maximum tolerated dose, or no-observed-adverse-effect level (NOAEL) for this species. Preclinical studies on related Entandrophragma extracts have not formally reported hepatotoxicity or renal toxicity, but the limonoid class as a whole includes compounds with known cytotoxic potential at higher concentrations, warranting caution. Drug interactions have not been studied; given the probable presence of CYP450-modulating triterpenoids—a documented property of limonoids in other Meliaceae—interactions with anticoagulants, immunosuppressants, and antimalarial drugs are theoretically plausible. Use during pregnancy and lactation is contraindicated in the absence of safety data; individuals with hepatic impairment or those taking polypharmacy regimens should avoid use entirely until formal safety evaluation is completed.